Background {#sec1-1}
==========

Warfarin is the commonly used anticoagulant for preventing thrombosis in a different subset of patients. Supratherapeutic dose of warfarin results in side effects like hematuria, vasculitis, interstitial nephritis, and hemorrhage.\[[@ref1][@ref2]\] Patients on chronic warfarin therapy are at increased risk of acute kidney injury (AKI) due to many reasons such as associated comorbidities, increased risk of hemorrhage, renal ischemia, atheroembolism, and allergic acute interstitial nephritis.\[[@ref1]\] We are reporting here a case of warfarin-related nephropathy (WRN), biopsy-proven in a 62-year-old man with chronic atrial fibrillation on long-term warfarin therapy with a history of ischemic stroke and dilated cardiomyopathy, where warfarin cannot be withheld.

Case Report {#sec1-2}
===========

A 62-year-old male was admitted with pain in abdomen as well as decreased appetite, vomiting, and red-colored urine. He was a known case of coronary artery disease post-percutaneous transluminal coronary angioplasty (PTCA)/stent with old ischemic stroke, chronic atrial fibrillation, dilated cardiomyopathy, and type 2 diabetes mellitus. He was kept on acenocoumarol 1 mg, aspirin 75 mg, atorvastatin 10 mg, and metoprolol 25 mg twice daily. He was on regular follow-up, and his acenocoumarol was recently increased to 1 and 2 mg alternate day to achieve the therapeutic international normalized ratio (INR). His baseline creatinine was 1.2 mg/dl. There was no history of exertional dyspnea, chest pain, palpitations, skin rash, decreased urine output, burning micturition, or pyuria. On physical examination, he was well nourished, no pallor and icterus was noticed, pulse rate was 80/min, and blood pressure was 130/80 mmHg. His serum creatinine was 5.35 mg/dl and INR was 5.4, with dysmorphic red blood cell (RBC) casts in the urine \[[Table 1](#T1){ref-type="table"}\]. A provisional diagnosis of AKI was made in the background of anticoagulation and was investigated further.

###### 

Laboratory investigations

  Investigations                 04/04/2018                             03/06/2018 Warfarin dose increased     05/07/2018 On admission                                              10/07/2018 Heparin switch over              21/07/2018 Discharge
  ------------------------------ -------------------------------------- -------------------------------------- -------------------------------------------------------------------- ------------------------------------------- -------------------------------------------
  Hb (g/dl)                      13.7                                   13.4                                   13.1                                                                 11.0                                        10.1
  TLC (cells/mm^3^)              7900                                   7000                                   8600                                                                 7200                                        6800
  Platelets (lakh/mm^3^)         1.25                                   1.6                                    1.79                                                                 1.89                                        2.1
  Creatinine (mg/dl)             1.40                                   1.3                                    5.35                                                                 3.2                                         1.8
  Bilirubin (mg/dl)              0.8                                    0.9                                    1.08                                                                 1.0                                         0.91
  Urine routine and microscopy   Albumin - nil RBC and pus cell - nil   Albumin - nil RBC and pus cell - nil   Albumin - 1+RBC - plenty and dysmorphic, RBC cast+Pus cell-6-8/hpf   Albumin - 1+RBC - 20-25/hpf Pus - 5-6/hpf   Albumin - nil RBC - 6-8/hpf Pus - 3-4/hpf
  PT INR                         1.61                                   1.3                                    5.4                                                                  1.4                                         1.8
  ANA/DSDNA                                                                                                    Negative                                                                                                         
  ANCA                                                                                                         Negative                                                                                                         
  C3/C4                                                                                                        Normal                                                                                                           

HB: Hemoglobin, TLC: Total leucocyte count, PT: Prothrombin time, INR: International normalized ratio, ANA: Anti nuclear antibody, ANCA: Antineutrophilic cytoplasmic antibodies, RBC: Red blood cells, DSDNA: Double-stranded DNA

The autoimmune markers were negative. 2D echocardiography showed global hypokinesia with ejection fraction of 35%. The ultrasonography showed bilateral normal-sized kidneys. Renal biopsy was planned in view of unexplained AKI after stopping acenocoumarol, suggestive of acute tubular necrosis with RBC casts and immunofluorescence studies were negative \[[Figure 1](#F1){ref-type="fig"}\]. Oral *N*-acetylcysteine (NAC) 1200 mg twice daily as well as oral prednisolone 30 mg/day was started. The serum creatinine started improving with the above treatment; meanwhile, he was managed with low molecular heparin before being restarted back with warfarin, with target INR of 1.5--2. The serum creatinine and INR 3-month postdischarge were 1.3 and 1.8, respectively.

![Sections stained with H and E (A). RBC casts in tubules (B). Normal glomerulus (C). Acute tubular necrosis](JFMPC-8-3045-g001){#F1}

Discussion {#sec1-3}
==========

Warfarin is a commonly used anticoagulant in clinical practice, used for both treatment as well as prophylaxis for prevention of arterial and venous thrombosis. WRN is defined as an increase in serum creatinine \>0.3 mg/dl, occurred within 1 week of an INR \>3.0 in patients on chronic warfarin therapy.\[[@ref3]\]

Kapoor *et al.* in 2008 described the entity called WRN as a cause of AKI in patients with hematuria while on warfarin therapy.\[[@ref2]\] Brodsky *et al.* described an association between anticoagulation with warfarin and INR (\>3.0) and worsening renal function.\[[@ref3]\] They published a series of nine patients who received renal biopsies over a 5-year period for unexplained AKI and hematuria during warfarin therapy.\[[@ref4]\] They retrospectively analyzed the biopsies and found extensive erythrocytes in Bowmen\'s space and tubules, and occlusive RBC casts in distal tubules without Tamm--Horsfall protein and active glomerulonephritis.\[[@ref4]\] WRN was a rare cause of AKI \<1% of the total kidney biopsies reviewed by them.\[[@ref4]\] Preexisting chronic kidney disease (CKD) doubles the incidence of WRN, 33% in CKD and 16.5% in non-CKD population.\[[@ref5][@ref6]\] Out of nine patients analyzed by them, four patients had a complete renal recovery, four became dialysis-dependent, and one developed CKD with no improvement in kidney function 2 months after biopsy.\[[@ref4]\]

Mendonca *et al.*, Golla *et al.*, and Conjeevaram *et al.* reported cases of WRN from India; we are reporting here a similar case.\[[@ref7][@ref8][@ref9]\]

Management of WRN in patients requiring long-term anticoagulation is ambiguous. Alternative to warfarin, other anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban are being increasingly used. However, their renal safety is not established. In the literature, dabigatran-related nephropathy was also reported.\[[@ref10]\] The best way to prevent WRN is to avoid excessive anticoagulation, drug interactions particularly with vitamin K antagonist and antibiotics, which interferes with warfarin metabolism and increases its drug level. In our case, patient had baseline serum creatinine of 1.2 mg/dl, and after 3 months of follow-up, his creatinine was 1.3 mg/dl, that is almost complete recovery occurred.\[[@ref4]\] Beneficial effects of steroid in WRN are not documented in studies; it may be useful due to its anti-inflammatory and antifibrotic action. Withholding of warfarin till therapeutic level attained reduces the glomerular hemorrhage and prevents further damage to renal tubules and hasten recovery of renal failure.\[[@ref8]\]

Conclusion {#sec1-4}
==========

AKI resulting from glomerular hemorrhage and tubular obstruction by RBC cast in patients on chronic warfarin therapy is a rare but serious complication. The supratherapeutic dose of warfarin increases the risk of AKI due to glomerular hematuria. Renal biopsy may be required for confirmation of diagnosis. Elderly patients, overanticoagulation, and underlying kidney diseases are the greatest risk factors. The treatment of biopsy-proven WRN is not clear; anticoagulants should be withdrawn and its effects should be reversed by using vitamin K. There is insufficient evidence regarding additional treatment with NAC or oral glucocorticoids. Clinical outcome in these patients is worst leading to the development of CKD and dialysis requirement. Care providers involved in the clinical care of patients on long-term anticoagulation should be aware of WRN and such patients should be monitored regularly for deterioration of renal function, change in coagulation profiles, and hematuria. Better understanding of WRN, though underdiagnosed, helps clinicians in early diagnosis, prognostication, timely therapy, and prevention from developing AKI, CKD, or dialysis dependence.
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